How to cite this paper
APA: Matiichuk, Y., Drapak, I., Kramarenko, S., Drapak, Y., Kostyshyn, L., Shtoyko, N & Matiychuk, V. (2025). Synthesis and antitumor activity of 2-cyanocinnamic acid amides and their indole analogues. Current Chemistry Letters, 14(1), 119-128.
Chicago/Turabian: Matiichuk, Y., Drapak, I., Kramarenko, S., Drapak, Y., Kostyshyn, L., Shtoyko, N & Matiychuk, V. 2025. "Synthesis and antitumor activity of 2-cyanocinnamic acid amides and their indole analogues." Current Chemistry Letters 14, no. 1 (2025): 119-128.
AMA: Matiichuk, Y., Drapak, I., Kramarenko, S., Drapak, Y., Kostyshyn, L., Shtoyko, N & Matiychuk, V. Synthesis and antitumor activity of 2-cyanocinnamic acid amides and their indole analogues. Current Chemistry Letters. 2025;14(1):119-128.
References
1 Tarleton M., Gilbert J., Robertson M.J., McCluskey A., and Sakoff J.A. (2011) Library synthesis and cytotoxicity of a family of 2-phenylacrylonitriles and discovery of an estrogen dependent breast cancer lead compound. Med. Chem. Comm., 2 (1) 31-37.
2 Tarleton M., Gilbert J., Sakoff J.A., and McCluskey A. (2012) Cytotoxic 2-phenyacrylnitriles, the importance of the cyanide moiety and discovery of potent broad spectrum cytotoxic agents. Eur. J. Med. Chem., 57 65-73.
3 Matiichuk Y., Horak Y., Chaban T., Chaban I., and Matiychuk V. (2022) Synthesis and anticancer properties of 3-furan-2-yl-2-(4-furan/thiophen-2-ylthiazol-2-yl)acrylonitrile derivatives. Curr. Chem. Lett., 11 (3) 269-274.
4 Spallarossa A., Caneva C., Caviglia M., Alfei S., Butini S., Campiani G., Gemma S., Brindisi M., Zisterer D. M., Bright S.A., Williams C.D., Crespan E., Maga G., Sanna G., Delogu I., Collu G., and Loddo R. (2015) Unconventional Knoevenagel-type Indoles: Synthesis and Cell-based Studies for the Identification of Pro-apoptotic Agents. Eur. J. Med. Chem., 102 648-660.
5 Leppänen J., Huuskonen J., Savolainen J., Nevalainen T., Taipale H., Vepsäläinen J., Gynther J., and Järvinen T. (2000) Synthesis of a water-soluble prodrug of entacapone. Bioorg. Med. Chem. Lett., 10 (17) 1967-1969.
6 Haj Salah K. B., Maingot M., Blayo A. L., M'Kadmi C., Damian M., Mary S., Cantel S., Neasta J., Oiry C., Péraldi-Roux S., Fernandez G., Romero G.G., Perello M., Marie J., Banères J.L., Fehrentz J.A., and Denoyelle S. (2020) Development of Nonpeptidic Inverse Agonists of the Ghrelin Receptor (GHSR) Based on the 1,2,4-Triazole Scaffold. J. Med. Chem., 63 (19) 10796-10815.
7 Demjén A., Alföldi R., Angyal A., Gyuris M., Hackler L. Jr., Szebeni G. J., Wölfling J., Puskás L. G., and Kanizsai I. (2018) Synthesis, cytotoxic characterization, and SAR study of imidazo[1,2-b]pyrazole-7-carboxamides. Arch. Pharm. (Weinheim), 351 (7) e1800062.
8 Desantis J., Nannetti G., Massari S., Barreca M. L., Manfroni G., Cecchetti V., Palù G., Goracci L., Loregian A., and Tabarrini O. (2017) Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity. Eur. J. Med. Chem., 138 128-139. Erratum in: (2018) Eur. J. Med. Chem., 156 302-303.
9 Ryabukhin S.V., Plaskon A. S., Volochnyuk D. M., Pipko S. E., Shivanyuk A. N., and Tolmachev A. A. (2007) Combinatorial Knoevenagel reactions. J. Comb. Chem., 9 (6) 1073-1078.
10 Amin S. A., Adhikari N., Jha T., and Gayen S. (2016) Exploring structural requirements of unconventional Knoevenagel-type indole derivatives as anticancer agents through comparative QSAR modeling approaches. Can. J. Chem., 94 7 637-644.
11 Developmental Therapeutics Program. Available online: https://dtp.cancer.gov/
12 Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M, Campbell H, Mayo J., and Boyd M. (1991) Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines. J. Nat. Cancer Inst., 83 (11) 757-766.
13 Boyd M. R., and Paull K. D. (1995) Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev. Res., 34 (2) 91-109.
14 Boyd M. R. (1997) The NCI in-vitro anticancer drug discovery screen: Concept, implementation and operation, 1985-1995, in: Teicher B. A. (Ed) Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. Humana Press: Totowa, NJ, USA. 23-42.
15 Shoemaker R. H. (2006) The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer, 6 813-823.
16 Rostom S. A. (2006) Synthesis and in vitro antitumor evaluation of some indeno[1,2-c]pyrazol(in)es substituted with sulfonamide, sulfonylurea(-thiourea) pharmacophores, and some derived thiazole ring systems. Bioorg. Med. Chem., 14 (19) 6475-6485.
1 Tarleton M., Gilbert J., Robertson M.J., McCluskey A., and Sakoff J.A. (2011) Library synthesis and cytotoxicity of a family of 2-phenylacrylonitriles and discovery of an estrogen dependent breast cancer lead compound. Med. Chem. Comm., 2 (1) 31-37.
2 Tarleton M., Gilbert J., Sakoff J.A., and McCluskey A. (2012) Cytotoxic 2-phenyacrylnitriles, the importance of the cyanide moiety and discovery of potent broad spectrum cytotoxic agents. Eur. J. Med. Chem., 57 65-73.
3 Matiichuk Y., Horak Y., Chaban T., Chaban I., and Matiychuk V. (2022) Synthesis and anticancer properties of 3-furan-2-yl-2-(4-furan/thiophen-2-ylthiazol-2-yl)acrylonitrile derivatives. Curr. Chem. Lett., 11 (3) 269-274.
4 Spallarossa A., Caneva C., Caviglia M., Alfei S., Butini S., Campiani G., Gemma S., Brindisi M., Zisterer D. M., Bright S.A., Williams C.D., Crespan E., Maga G., Sanna G., Delogu I., Collu G., and Loddo R. (2015) Unconventional Knoevenagel-type Indoles: Synthesis and Cell-based Studies for the Identification of Pro-apoptotic Agents. Eur. J. Med. Chem., 102 648-660.
5 Leppänen J., Huuskonen J., Savolainen J., Nevalainen T., Taipale H., Vepsäläinen J., Gynther J., and Järvinen T. (2000) Synthesis of a water-soluble prodrug of entacapone. Bioorg. Med. Chem. Lett., 10 (17) 1967-1969.
6 Haj Salah K. B., Maingot M., Blayo A. L., M'Kadmi C., Damian M., Mary S., Cantel S., Neasta J., Oiry C., Péraldi-Roux S., Fernandez G., Romero G.G., Perello M., Marie J., Banères J.L., Fehrentz J.A., and Denoyelle S. (2020) Development of Nonpeptidic Inverse Agonists of the Ghrelin Receptor (GHSR) Based on the 1,2,4-Triazole Scaffold. J. Med. Chem., 63 (19) 10796-10815.
7 Demjén A., Alföldi R., Angyal A., Gyuris M., Hackler L. Jr., Szebeni G. J., Wölfling J., Puskás L. G., and Kanizsai I. (2018) Synthesis, cytotoxic characterization, and SAR study of imidazo[1,2-b]pyrazole-7-carboxamides. Arch. Pharm. (Weinheim), 351 (7) e1800062.
8 Desantis J., Nannetti G., Massari S., Barreca M. L., Manfroni G., Cecchetti V., Palù G., Goracci L., Loregian A., and Tabarrini O. (2017) Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity. Eur. J. Med. Chem., 138 128-139. Erratum in: (2018) Eur. J. Med. Chem., 156 302-303.
9 Ryabukhin S.V., Plaskon A. S., Volochnyuk D. M., Pipko S. E., Shivanyuk A. N., and Tolmachev A. A. (2007) Combinatorial Knoevenagel reactions. J. Comb. Chem., 9 (6) 1073-1078.
10 Amin S. A., Adhikari N., Jha T., and Gayen S. (2016) Exploring structural requirements of unconventional Knoevenagel-type indole derivatives as anticancer agents through comparative QSAR modeling approaches. Can. J. Chem., 94 7 637-644.
11 Developmental Therapeutics Program. Available online: https://dtp.cancer.gov/
12 Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M, Campbell H, Mayo J., and Boyd M. (1991) Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines. J. Nat. Cancer Inst., 83 (11) 757-766.
13 Boyd M. R., and Paull K. D. (1995) Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev. Res., 34 (2) 91-109.
14 Boyd M. R. (1997) The NCI in-vitro anticancer drug discovery screen: Concept, implementation and operation, 1985-1995, in: Teicher B. A. (Ed) Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. Humana Press: Totowa, NJ, USA. 23-42.
15 Shoemaker R. H. (2006) The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer, 6 813-823.
16 Rostom S. A. (2006) Synthesis and in vitro antitumor evaluation of some indeno[1,2-c]pyrazol(in)es substituted with sulfonamide, sulfonylurea(-thiourea) pharmacophores, and some derived thiazole ring systems. Bioorg. Med. Chem., 14 (19) 6475-6485.